nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—ABCG2—Topotecan—cervical cancer	0.295	0.634	CbGbCtD
Regorafenib—ABCB1—Topotecan—cervical cancer	0.106	0.229	CbGbCtD
Regorafenib—CYP3A4—Topotecan—cervical cancer	0.0637	0.137	CbGbCtD
Regorafenib—NTRK1—decidua—cervical cancer	0.00498	0.0201	CbGeAlD
Regorafenib—FGFR2—exocrine gland—cervical cancer	0.0046	0.0186	CbGeAlD
Regorafenib—Mucosal inflammation—Topotecan—cervical cancer	0.00433	0.107	CcSEcCtD
Regorafenib—FRK—renal system—cervical cancer	0.00405	0.0163	CbGeAlD
Regorafenib—DDR2—uterine cervix—cervical cancer	0.00389	0.0157	CbGeAlD
Regorafenib—DDR2—decidua—cervical cancer	0.0037	0.0149	CbGeAlD
Regorafenib—DDR2—endometrium—cervical cancer	0.00352	0.0142	CbGeAlD
Regorafenib—DDR2—mammalian vulva—cervical cancer	0.0034	0.0137	CbGeAlD
Regorafenib—FRK—female reproductive system—cervical cancer	0.00325	0.0131	CbGeAlD
Regorafenib—DDR2—uterus—cervical cancer	0.00324	0.0131	CbGeAlD
Regorafenib—KIT—exocrine gland—cervical cancer	0.0032	0.0129	CbGeAlD
Regorafenib—DDR2—female reproductive system—cervical cancer	0.00291	0.0117	CbGeAlD
Regorafenib—MAPK11—female reproductive system—cervical cancer	0.00276	0.0111	CbGeAlD
Regorafenib—DDR2—female gonad—cervical cancer	0.00265	0.0107	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00264	0.0649	CcSEcCtD
Regorafenib—DDR2—vagina—cervical cancer	0.00263	0.0106	CbGeAlD
Regorafenib—MAPK11—female gonad—cervical cancer	0.00251	0.0101	CbGeAlD
Regorafenib—BRAF—endometrium—cervical cancer	0.00248	0.01	CbGeAlD
Regorafenib—FLT4—epithelium—cervical cancer	0.00239	0.00962	CbGeAlD
Regorafenib—FGFR1—uterine cervix—cervical cancer	0.00234	0.00941	CbGeAlD
Regorafenib—EPHX2—mammalian vulva—cervical cancer	0.0023	0.00926	CbGeAlD
Regorafenib—BRAF—uterus—cervical cancer	0.00229	0.00923	CbGeAlD
Regorafenib—FLT4—decidua—cervical cancer	0.00226	0.00909	CbGeAlD
Regorafenib—UGT1A9—renal system—cervical cancer	0.00225	0.00905	CbGeAlD
Regorafenib—FGFR1—decidua—cervical cancer	0.00223	0.00897	CbGeAlD
Regorafenib—EPHX2—uterus—cervical cancer	0.00219	0.00882	CbGeAlD
Regorafenib—Neoplasm—Topotecan—cervical cancer	0.00217	0.0534	CcSEcCtD
Regorafenib—RET—epithelium—cervical cancer	0.00211	0.0085	CbGeAlD
Regorafenib—FGFR1—mammalian vulva—cervical cancer	0.00204	0.00823	CbGeAlD
Regorafenib—FGFR2—epithelium—cervical cancer	0.002	0.00807	CbGeAlD
Regorafenib—RET—decidua—cervical cancer	0.00199	0.00802	CbGeAlD
Regorafenib—FGFR2—uterine cervix—cervical cancer	0.00199	0.008	CbGeAlD
Regorafenib—EPHA2—epithelium—cervical cancer	0.00197	0.00793	CbGeAlD
Regorafenib—RET—renal system—cervical cancer	0.00196	0.00788	CbGeAlD
Regorafenib—EPHA2—uterine cervix—cervical cancer	0.00195	0.00786	CbGeAlD
Regorafenib—FGFR1—uterus—cervical cancer	0.00195	0.00784	CbGeAlD
Regorafenib—TEK—epithelium—cervical cancer	0.00192	0.00774	CbGeAlD
Regorafenib—BRAF—female gonad—cervical cancer	0.00187	0.00755	CbGeAlD
Regorafenib—BRAF—vagina—cervical cancer	0.00186	0.0075	CbGeAlD
Regorafenib—EPHA2—decidua—cervical cancer	0.00186	0.00749	CbGeAlD
Regorafenib—FGFR2—renal system—cervical cancer	0.00186	0.00749	CbGeAlD
Regorafenib—FLT1—epithelium—cervical cancer	0.00186	0.00748	CbGeAlD
Regorafenib—RAF1—epithelium—cervical cancer	0.00185	0.00744	CbGeAlD
Regorafenib—FLT1—uterine cervix—cervical cancer	0.00184	0.00742	CbGeAlD
Regorafenib—RAF1—uterine cervix—cervical cancer	0.00183	0.00737	CbGeAlD
Regorafenib—TEK—decidua—cervical cancer	0.00181	0.00731	CbGeAlD
Regorafenib—EPHX2—female gonad—cervical cancer	0.00179	0.00721	CbGeAlD
Regorafenib—TEK—renal system—cervical cancer	0.00178	0.00718	CbGeAlD
Regorafenib—EPHX2—vagina—cervical cancer	0.00178	0.00717	CbGeAlD
Regorafenib—FLT4—female reproductive system—cervical cancer	0.00177	0.00715	CbGeAlD
Regorafenib—EPHA2—endometrium—cervical cancer	0.00177	0.00711	CbGeAlD
Regorafenib—FLT1—decidua—cervical cancer	0.00175	0.00707	CbGeAlD
Regorafenib—RAF1—decidua—cervical cancer	0.00174	0.00703	CbGeAlD
Regorafenib—FLT1—renal system—cervical cancer	0.00172	0.00694	CbGeAlD
Regorafenib—TEK—endometrium—cervical cancer	0.00172	0.00694	CbGeAlD
Regorafenib—RAF1—renal system—cervical cancer	0.00171	0.0069	CbGeAlD
Regorafenib—EPHA2—mammalian vulva—cervical cancer	0.00171	0.00688	CbGeAlD
Regorafenib—DDR2—lymph node—cervical cancer	0.0017	0.00686	CbGeAlD
Regorafenib—FLT1—endometrium—cervical cancer	0.00167	0.00671	CbGeAlD
Regorafenib—RAF1—endometrium—cervical cancer	0.00166	0.00667	CbGeAlD
Regorafenib—FGFR2—uterus—cervical cancer	0.00166	0.00667	CbGeAlD
Regorafenib—PDGFRA—decidua—cervical cancer	0.00164	0.00662	CbGeAlD
Regorafenib—MAPK11—lymph node—cervical cancer	0.00161	0.00651	CbGeAlD
Regorafenib—FLT4—female gonad—cervical cancer	0.00161	0.0065	CbGeAlD
Regorafenib—PDGFRA—renal system—cervical cancer	0.00161	0.0065	CbGeAlD
Regorafenib—FLT1—mammalian vulva—cervical cancer	0.00161	0.00649	CbGeAlD
Regorafenib—RAF1—mammalian vulva—cervical cancer	0.0016	0.00645	CbGeAlD
Regorafenib—FGFR1—female gonad—cervical cancer	0.00159	0.00642	CbGeAlD
Regorafenib—TEK—uterus—cervical cancer	0.00159	0.00639	CbGeAlD
Regorafenib—FGFR1—vagina—cervical cancer	0.00158	0.00638	CbGeAlD
Regorafenib—KDR—epithelium—cervical cancer	0.00157	0.00632	CbGeAlD
Regorafenib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00157	0.0386	CcSEcCtD
Regorafenib—KDR—uterine cervix—cervical cancer	0.00156	0.00627	CbGeAlD
Regorafenib—UGT1A1—renal system—cervical cancer	0.00154	0.0062	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00153	0.0378	CcSEcCtD
Regorafenib—FLT1—uterus—cervical cancer	0.00153	0.00618	CbGeAlD
Regorafenib—RAF1—uterus—cervical cancer	0.00153	0.00615	CbGeAlD
Regorafenib—FGFR2—female reproductive system—cervical cancer	0.00149	0.006	CbGeAlD
Regorafenib—KDR—decidua—cervical cancer	0.00148	0.00597	CbGeAlD
Regorafenib—EPHA2—female reproductive system—cervical cancer	0.00146	0.00589	CbGeAlD
Regorafenib—KDR—renal system—cervical cancer	0.00146	0.00587	CbGeAlD
Regorafenib—PDGFRA—uterus—cervical cancer	0.00144	0.00579	CbGeAlD
Regorafenib—TEK—female reproductive system—cervical cancer	0.00143	0.00575	CbGeAlD
Regorafenib—KDR—endometrium—cervical cancer	0.00141	0.00567	CbGeAlD
Regorafenib—Neutropenia—Topotecan—cervical cancer	0.00141	0.0346	CcSEcCtD
Regorafenib—KIT—epithelium—cervical cancer	0.00139	0.0056	CbGeAlD
Regorafenib—FLT1—female reproductive system—cervical cancer	0.00138	0.00556	CbGeAlD
Regorafenib—KIT—uterine cervix—cervical cancer	0.00138	0.00556	CbGeAlD
Regorafenib—RAF1—female reproductive system—cervical cancer	0.00137	0.00553	CbGeAlD
Regorafenib—KDR—mammalian vulva—cervical cancer	0.00136	0.00549	CbGeAlD
Regorafenib—PDGFRB—epithelium—cervical cancer	0.00136	0.00547	CbGeAlD
Regorafenib—FGFR2—female gonad—cervical cancer	0.00135	0.00546	CbGeAlD
Regorafenib—PDGFRB—uterine cervix—cervical cancer	0.00135	0.00543	CbGeAlD
Regorafenib—Infestation—Topotecan—cervical cancer	0.00134	0.033	CcSEcCtD
Regorafenib—Infestation NOS—Topotecan—cervical cancer	0.00134	0.033	CcSEcCtD
Regorafenib—EPHA2—female gonad—cervical cancer	0.00133	0.00536	CbGeAlD
Regorafenib—EPHA2—vagina—cervical cancer	0.00132	0.00533	CbGeAlD
Regorafenib—KIT—decidua—cervical cancer	0.00131	0.00529	CbGeAlD
Regorafenib—Stomatitis—Topotecan—cervical cancer	0.00131	0.0322	CcSEcCtD
Regorafenib—TEK—female gonad—cervical cancer	0.0013	0.00523	CbGeAlD
Regorafenib—KDR—uterus—cervical cancer	0.0013	0.00523	CbGeAlD
Regorafenib—PDGFRA—female reproductive system—cervical cancer	0.00129	0.00521	CbGeAlD
Regorafenib—KIT—renal system—cervical cancer	0.00129	0.0052	CbGeAlD
Regorafenib—PDGFRB—decidua—cervical cancer	0.00128	0.00517	CbGeAlD
Regorafenib—Hepatobiliary disease—Topotecan—cervical cancer	0.00127	0.0312	CcSEcCtD
Regorafenib—PDGFRB—renal system—cervical cancer	0.00126	0.00508	CbGeAlD
Regorafenib—FLT1—female gonad—cervical cancer	0.00126	0.00506	CbGeAlD
Regorafenib—RAF1—female gonad—cervical cancer	0.00125	0.00503	CbGeAlD
Regorafenib—FLT1—vagina—cervical cancer	0.00125	0.00503	CbGeAlD
Regorafenib—KIT—endometrium—cervical cancer	0.00125	0.00503	CbGeAlD
Regorafenib—RAF1—vagina—cervical cancer	0.00124	0.005	CbGeAlD
Regorafenib—PDGFRB—endometrium—cervical cancer	0.00122	0.00491	CbGeAlD
Regorafenib—Haemoglobin—Topotecan—cervical cancer	0.00121	0.0298	CcSEcCtD
Regorafenib—KIT—mammalian vulva—cervical cancer	0.00121	0.00486	CbGeAlD
Regorafenib—BRAF—lymph node—cervical cancer	0.0012	0.00485	CbGeAlD
Regorafenib—Haemorrhage—Topotecan—cervical cancer	0.0012	0.0296	CcSEcCtD
Regorafenib—ABL1—uterine cervix—cervical cancer	0.0012	0.00484	CbGeAlD
Regorafenib—PDGFRB—mammalian vulva—cervical cancer	0.00118	0.00475	CbGeAlD
Regorafenib—PDGFRA—female gonad—cervical cancer	0.00118	0.00474	CbGeAlD
Regorafenib—PDGFRA—vagina—cervical cancer	0.00117	0.00471	CbGeAlD
Regorafenib—KDR—female reproductive system—cervical cancer	0.00117	0.0047	CbGeAlD
Regorafenib—EPHX2—lymph node—cervical cancer	0.00115	0.00464	CbGeAlD
Regorafenib—KIT—uterus—cervical cancer	0.00115	0.00463	CbGeAlD
Regorafenib—ABL1—decidua—cervical cancer	0.00114	0.00461	CbGeAlD
Regorafenib—ABL1—renal system—cervical cancer	0.00112	0.00453	CbGeAlD
Regorafenib—PDGFRB—uterus—cervical cancer	0.00112	0.00452	CbGeAlD
Regorafenib—Angiopathy—Topotecan—cervical cancer	0.00109	0.0269	CcSEcCtD
Regorafenib—ABL1—endometrium—cervical cancer	0.00109	0.00438	CbGeAlD
Regorafenib—Mediastinal disorder—Topotecan—cervical cancer	0.00108	0.0267	CcSEcCtD
Regorafenib—Alopecia—Topotecan—cervical cancer	0.00106	0.0262	CcSEcCtD
Regorafenib—KDR—female gonad—cervical cancer	0.00106	0.00428	CbGeAlD
Regorafenib—KDR—vagina—cervical cancer	0.00105	0.00425	CbGeAlD
Regorafenib—ABL1—mammalian vulva—cervical cancer	0.00105	0.00423	CbGeAlD
Regorafenib—Malnutrition—Topotecan—cervical cancer	0.00105	0.0258	CcSEcCtD
Regorafenib—FLT4—lymph node—cervical cancer	0.00104	0.00418	CbGeAlD
Regorafenib—KIT—female reproductive system—cervical cancer	0.00103	0.00416	CbGeAlD
Regorafenib—FGFR1—lymph node—cervical cancer	0.00102	0.00413	CbGeAlD
Regorafenib—PDGFRB—female reproductive system—cervical cancer	0.00101	0.00407	CbGeAlD
Regorafenib—ABL1—uterus—cervical cancer	0.001	0.00403	CbGeAlD
Regorafenib—Anaemia—Topotecan—cervical cancer	0.000968	0.0238	CcSEcCtD
Regorafenib—KIT—female gonad—cervical cancer	0.00094	0.00379	CbGeAlD
Regorafenib—Leukopenia—Topotecan—cervical cancer	0.000938	0.0231	CcSEcCtD
Regorafenib—KIT—vagina—cervical cancer	0.000934	0.00377	CbGeAlD
Regorafenib—PDGFRB—female gonad—cervical cancer	0.000918	0.0037	CbGeAlD
Regorafenib—RET—lymph node—cervical cancer	0.000916	0.00369	CbGeAlD
Regorafenib—PDGFRB—vagina—cervical cancer	0.000913	0.00368	CbGeAlD
Regorafenib—ABL1—female reproductive system—cervical cancer	0.000899	0.00362	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000886	0.0218	CcSEcCtD
Regorafenib—EPHA2—lymph node—cervical cancer	0.000855	0.00345	CbGeAlD
Regorafenib—Infection—Topotecan—cervical cancer	0.00085	0.0209	CcSEcCtD
Regorafenib—Nervous system disorder—Topotecan—cervical cancer	0.000839	0.0206	CcSEcCtD
Regorafenib—Thrombocytopenia—Topotecan—cervical cancer	0.000837	0.0206	CcSEcCtD
Regorafenib—TEK—lymph node—cervical cancer	0.000835	0.00336	CbGeAlD
Regorafenib—Skin disorder—Topotecan—cervical cancer	0.000831	0.0205	CcSEcCtD
Regorafenib—ABL1—female gonad—cervical cancer	0.000818	0.0033	CbGeAlD
Regorafenib—ABL1—vagina—cervical cancer	0.000813	0.00328	CbGeAlD
Regorafenib—FLT1—lymph node—cervical cancer	0.000807	0.00325	CbGeAlD
Regorafenib—RAF1—lymph node—cervical cancer	0.000802	0.00323	CbGeAlD
Regorafenib—ABCG2—uterine cervix—cervical cancer	0.000757	0.00305	CbGeAlD
Regorafenib—PDGFRA—lymph node—cervical cancer	0.000756	0.00305	CbGeAlD
Regorafenib—Decreased appetite—Topotecan—cervical cancer	0.000743	0.0183	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Topotecan—cervical cancer	0.000738	0.0182	CcSEcCtD
Regorafenib—Fatigue—Topotecan—cervical cancer	0.000737	0.0182	CcSEcCtD
Regorafenib—Pain—Topotecan—cervical cancer	0.000731	0.018	CcSEcCtD
Regorafenib—CYP2C8—renal system—cervical cancer	0.000728	0.00294	CbGeAlD
Regorafenib—ABCG2—decidua—cervical cancer	0.000721	0.00291	CbGeAlD
Regorafenib—CYP2C8—endometrium—cervical cancer	0.000704	0.00284	CbGeAlD
Regorafenib—Gastrointestinal pain—Topotecan—cervical cancer	0.000699	0.0172	CcSEcCtD
Regorafenib—ABCG2—endometrium—cervical cancer	0.000685	0.00276	CbGeAlD
Regorafenib—KDR—lymph node—cervical cancer	0.000682	0.00275	CbGeAlD
Regorafenib—Abdominal pain—Topotecan—cervical cancer	0.000676	0.0166	CcSEcCtD
Regorafenib—Body temperature increased—Topotecan—cervical cancer	0.000676	0.0166	CcSEcCtD
Regorafenib—ABCG2—mammalian vulva—cervical cancer	0.000662	0.00267	CbGeAlD
Regorafenib—CYP2B6—renal system—cervical cancer	0.000653	0.00263	CbGeAlD
Regorafenib—ABCG2—uterus—cervical cancer	0.000631	0.00254	CbGeAlD
Regorafenib—Asthenia—Topotecan—cervical cancer	0.000614	0.0151	CcSEcCtD
Regorafenib—CYP2C19—vagina—cervical cancer	0.000604	0.00244	CbGeAlD
Regorafenib—KIT—lymph node—cervical cancer	0.000604	0.00244	CbGeAlD
Regorafenib—PDGFRB—lymph node—cervical cancer	0.00059	0.00238	CbGeAlD
Regorafenib—Diarrhoea—Topotecan—cervical cancer	0.000585	0.0144	CcSEcCtD
Regorafenib—CYP2C8—female reproductive system—cervical cancer	0.000583	0.00235	CbGeAlD
Regorafenib—Vomiting—Topotecan—cervical cancer	0.000544	0.0134	CcSEcCtD
Regorafenib—Rash—Topotecan—cervical cancer	0.000539	0.0133	CcSEcCtD
Regorafenib—Dermatitis—Topotecan—cervical cancer	0.000539	0.0133	CcSEcCtD
Regorafenib—Headache—Topotecan—cervical cancer	0.000536	0.0132	CcSEcCtD
Regorafenib—CYP2C8—vagina—cervical cancer	0.000528	0.00213	CbGeAlD
Regorafenib—ABL1—lymph node—cervical cancer	0.000526	0.00212	CbGeAlD
Regorafenib—CYP2B6—female reproductive system—cervical cancer	0.000523	0.00211	CbGeAlD
Regorafenib—CYP2C9—female reproductive system—cervical cancer	0.000518	0.00209	CbGeAlD
Regorafenib—ABCG2—female gonad—cervical cancer	0.000516	0.00208	CbGeAlD
Regorafenib—ABCG2—vagina—cervical cancer	0.000513	0.00207	CbGeAlD
Regorafenib—Nausea—Topotecan—cervical cancer	0.000508	0.0125	CcSEcCtD
Regorafenib—CYP3A4—renal system—cervical cancer	0.000493	0.00199	CbGeAlD
Regorafenib—CYP2B6—vagina—cervical cancer	0.000473	0.00191	CbGeAlD
Regorafenib—CYP3A4—female reproductive system—cervical cancer	0.000395	0.00159	CbGeAlD
Regorafenib—ABCB1—epithelium—cervical cancer	0.000377	0.00152	CbGeAlD
Regorafenib—ABCB1—uterine cervix—cervical cancer	0.000373	0.0015	CbGeAlD
Regorafenib—ABCB1—decidua—cervical cancer	0.000356	0.00143	CbGeAlD
Regorafenib—ABCB1—renal system—cervical cancer	0.000349	0.00141	CbGeAlD
Regorafenib—ABCB1—endometrium—cervical cancer	0.000338	0.00136	CbGeAlD
Regorafenib—ABCG2—lymph node—cervical cancer	0.000332	0.00134	CbGeAlD
Regorafenib—ABCB1—mammalian vulva—cervical cancer	0.000327	0.00132	CbGeAlD
Regorafenib—ABCB1—uterus—cervical cancer	0.000311	0.00125	CbGeAlD
Regorafenib—ABCB1—female reproductive system—cervical cancer	0.00028	0.00113	CbGeAlD
Regorafenib—ABCB1—female gonad—cervical cancer	0.000255	0.00103	CbGeAlD
Regorafenib—ABCB1—vagina—cervical cancer	0.000253	0.00102	CbGeAlD
Regorafenib—ABCB1—lymph node—cervical cancer	0.000164	0.000659	CbGeAlD
Regorafenib—FLT4—Signaling Pathways—STAT3—cervical cancer	3.59e-05	0.000146	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—CTNNB1—cervical cancer	3.59e-05	0.000145	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—EGFR—cervical cancer	3.58e-05	0.000145	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TERT—cervical cancer	3.57e-05	0.000145	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HES1—cervical cancer	3.5e-05	0.000142	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—CTNNB1—cervical cancer	3.49e-05	0.000142	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HES1—cervical cancer	3.47e-05	0.000141	CbGpPWpGaD
Regorafenib—FGFR2—Disease—NOTCH1—cervical cancer	3.46e-05	0.000141	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—FGFR3—cervical cancer	3.46e-05	0.000141	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MTOR—cervical cancer	3.46e-05	0.00014	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—MTOR—cervical cancer	3.46e-05	0.00014	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—CD4—cervical cancer	3.45e-05	0.00014	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—STAT3—cervical cancer	3.45e-05	0.00014	CbGpPWpGaD
Regorafenib—FGFR1—Disease—FGFR3—cervical cancer	3.44e-05	0.00014	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—FGFR3—cervical cancer	3.43e-05	0.000139	CbGpPWpGaD
Regorafenib—RAF1—Disease—HES1—cervical cancer	3.43e-05	0.000139	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CASP8—cervical cancer	3.42e-05	0.000139	CbGpPWpGaD
Regorafenib—KIT—Disease—NOTCH1—cervical cancer	3.4e-05	0.000138	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—EGFR—cervical cancer	3.39e-05	0.000138	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MTHFR—cervical cancer	3.38e-05	0.000137	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—TERT—cervical cancer	3.37e-05	0.000137	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CA9—cervical cancer	3.36e-05	0.000136	CbGpPWpGaD
Regorafenib—KIT—Immune System—CASP8—cervical cancer	3.36e-05	0.000136	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—FGFR3—cervical cancer	3.35e-05	0.000136	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—EGFR—cervical cancer	3.33e-05	0.000135	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NOTCH2—cervical cancer	3.28e-05	0.000133	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—FGFR3—cervical cancer	3.27e-05	0.000133	CbGpPWpGaD
Regorafenib—ABL1—Immune System—FGFR3—cervical cancer	3.26e-05	0.000132	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—EGFR—cervical cancer	3.26e-05	0.000132	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—EGFR—cervical cancer	3.26e-05	0.000132	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—NOTCH1—cervical cancer	3.25e-05	0.000132	CbGpPWpGaD
Regorafenib—FGFR1—Disease—NOTCH1—cervical cancer	3.23e-05	0.000131	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—NOTCH1—cervical cancer	3.22e-05	0.000131	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HES1—cervical cancer	3.21e-05	0.00013	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—EGFR—cervical cancer	3.2e-05	0.00013	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—CTNNB1—cervical cancer	3.2e-05	0.00013	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CASP8—cervical cancer	3.19e-05	0.000129	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—CASP3—cervical cancer	3.18e-05	0.000129	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CASP8—cervical cancer	3.18e-05	0.000129	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—EGFR—cervical cancer	3.16e-05	0.000128	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HES1—cervical cancer	3.16e-05	0.000128	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—STAT3—cervical cancer	3.15e-05	0.000128	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—EGFR—cervical cancer	3.15e-05	0.000128	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—EGFR—cervical cancer	3.13e-05	0.000127	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—FGFR3—cervical cancer	3.09e-05	0.000125	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NOTCH1—cervical cancer	3.07e-05	0.000125	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—CTNNB1—cervical cancer	3.07e-05	0.000125	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TERT—cervical cancer	3.07e-05	0.000124	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—MTOR—cervical cancer	3.06e-05	0.000124	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD4—cervical cancer	3.06e-05	0.000124	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TERT—cervical cancer	3.04e-05	0.000123	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—EGFR—cervical cancer	3.04e-05	0.000123	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—EGFR—cervical cancer	3.03e-05	0.000123	CbGpPWpGaD
Regorafenib—RAF1—Disease—MTHFR—cervical cancer	3.01e-05	0.000122	CbGpPWpGaD
Regorafenib—RAF1—Disease—TERT—cervical cancer	3e-05	0.000122	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CA9—cervical cancer	3e-05	0.000122	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HES1—cervical cancer	3e-05	0.000122	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HES1—cervical cancer	2.99e-05	0.000121	CbGpPWpGaD
Regorafenib—RAF1—Immune System—FGFR3—cervical cancer	2.98e-05	0.000121	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CA9—cervical cancer	2.93e-05	0.000119	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NOTCH2—cervical cancer	2.93e-05	0.000119	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NOTCH1—cervical cancer	2.9e-05	0.000118	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	2.89e-05	0.000117	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—EGFR—cervical cancer	2.87e-05	0.000116	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CASP8—cervical cancer	2.86e-05	0.000116	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—EGFR—cervical cancer	2.84e-05	0.000115	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TERT—cervical cancer	2.82e-05	0.000114	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—FGFR3—cervical cancer	2.81e-05	0.000114	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—MTOR—cervical cancer	2.81e-05	0.000114	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD4—cervical cancer	2.81e-05	0.000114	CbGpPWpGaD
Regorafenib—BRAF—Disease—MTOR—cervical cancer	2.8e-05	0.000114	CbGpPWpGaD
Regorafenib—BRAF—Disease—CD4—cervical cancer	2.8e-05	0.000113	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CASP8—cervical cancer	2.79e-05	0.000113	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—FGFR3—cervical cancer	2.79e-05	0.000113	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—EGFR—cervical cancer	2.77e-05	0.000112	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TERT—cervical cancer	2.77e-05	0.000112	CbGpPWpGaD
Regorafenib—KIT—Immune System—MTOR—cervical cancer	2.76e-05	0.000112	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD4—cervical cancer	2.76e-05	0.000112	CbGpPWpGaD
Regorafenib—RAF1—Disease—FGFR3—cervical cancer	2.75e-05	0.000112	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CA9—cervical cancer	2.74e-05	0.000111	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—cervical cancer	2.74e-05	0.000111	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—EGFR—cervical cancer	2.73e-05	0.000111	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CTNNB1—cervical cancer	2.72e-05	0.00011	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HES1—cervical cancer	2.69e-05	0.000109	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—STAT3—cervical cancer	2.67e-05	0.000109	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NOTCH1—cervical cancer	2.64e-05	0.000107	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TERT—cervical cancer	2.62e-05	0.000107	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—MTOR—cervical cancer	2.62e-05	0.000106	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TERT—cervical cancer	2.62e-05	0.000106	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NOTCH1—cervical cancer	2.62e-05	0.000106	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD4—cervical cancer	2.62e-05	0.000106	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—MTOR—cervical cancer	2.61e-05	0.000106	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD4—cervical cancer	2.61e-05	0.000106	CbGpPWpGaD
Regorafenib—FGFR2—Disease—MTOR—cervical cancer	2.6e-05	0.000105	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—MTHFR—cervical cancer	2.59e-05	0.000105	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—MTHFR—cervical cancer	2.59e-05	0.000105	CbGpPWpGaD
Regorafenib—FGFR2—Disease—CD4—cervical cancer	2.59e-05	0.000105	CbGpPWpGaD
Regorafenib—RAF1—Disease—NOTCH1—cervical cancer	2.59e-05	0.000105	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—FGFR3—cervical cancer	2.58e-05	0.000105	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—cervical cancer	2.58e-05	0.000105	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CASP8—cervical cancer	2.55e-05	0.000104	CbGpPWpGaD
Regorafenib—KIT—Disease—MTOR—cervical cancer	2.55e-05	0.000103	CbGpPWpGaD
Regorafenib—KIT—Disease—CD4—cervical cancer	2.55e-05	0.000103	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—FGFR3—cervical cancer	2.54e-05	0.000103	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—EGFR—cervical cancer	2.53e-05	0.000103	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CTNNB1—cervical cancer	2.49e-05	0.000101	CbGpPWpGaD
Regorafenib—BRAF—Disease—CTNNB1—cervical cancer	2.48e-05	0.000101	CbGpPWpGaD
Regorafenib—KIT—Immune System—CTNNB1—cervical cancer	2.45e-05	9.94e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MTOR—cervical cancer	2.44e-05	9.89e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—EGFR—cervical cancer	2.43e-05	9.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—EGFR—cervical cancer	2.43e-05	9.87e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	2.43e-05	9.85e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NOTCH1—cervical cancer	2.43e-05	9.85e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MTOR—cervical cancer	2.42e-05	9.82e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CD4—cervical cancer	2.42e-05	9.8e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MTOR—cervical cancer	2.41e-05	9.8e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CD4—cervical cancer	2.41e-05	9.78e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—FGFR3—cervical cancer	2.41e-05	9.78e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—FGFR3—cervical cancer	2.4e-05	9.75e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HES1—cervical cancer	2.4e-05	9.74e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NOTCH1—cervical cancer	2.38e-05	9.67e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—STAT3—cervical cancer	2.37e-05	9.61e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—cervical cancer	2.36e-05	9.58e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TERT—cervical cancer	2.36e-05	9.57e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—MTOR—cervical cancer	2.36e-05	9.56e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD4—cervical cancer	2.35e-05	9.54e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CTNNB1—cervical cancer	2.32e-05	9.43e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CTNNB1—cervical cancer	2.32e-05	9.41e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MTOR—cervical cancer	2.3e-05	9.35e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—CTNNB1—cervical cancer	2.3e-05	9.34e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—MTOR—cervical cancer	2.3e-05	9.31e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD4—cervical cancer	2.29e-05	9.3e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NOTCH1—cervical cancer	2.26e-05	9.18e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—CTNNB1—cervical cancer	2.26e-05	9.17e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NOTCH1—cervical cancer	2.26e-05	9.15e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CASP3—cervical cancer	2.24e-05	9.1e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—MTHFR—cervical cancer	2.2e-05	8.92e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MTOR—cervical cancer	2.17e-05	8.83e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—STAT3—cervical cancer	2.17e-05	8.82e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CD4—cervical cancer	2.17e-05	8.81e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—STAT3—cervical cancer	2.16e-05	8.79e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—FGFR3—cervical cancer	2.16e-05	8.78e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CTNNB1—cervical cancer	2.16e-05	8.77e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—EGFR—cervical cancer	2.15e-05	8.73e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CTNNB1—cervical cancer	2.15e-05	8.71e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CTNNB1—cervical cancer	2.14e-05	8.68e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—STAT3—cervical cancer	2.13e-05	8.66e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CASP3—cervical cancer	2.12e-05	8.6e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TERT—cervical cancer	2.1e-05	8.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—MTOR—cervical cancer	2.1e-05	8.52e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD4—cervical cancer	2.1e-05	8.5e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CTNNB1—cervical cancer	2.09e-05	8.47e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CTNNB1—cervical cancer	2.04e-05	8.29e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—cervical cancer	2.04e-05	8.28e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CTNNB1—cervical cancer	2.03e-05	8.26e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NOTCH1—cervical cancer	2.03e-05	8.25e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—STAT3—cervical cancer	2.03e-05	8.22e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—STAT3—cervical cancer	2.02e-05	8.2e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—STAT3—cervical cancer	2.01e-05	8.14e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MTOR—cervical cancer	1.98e-05	8.04e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—EGFR—cervical cancer	1.98e-05	8.02e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—STAT3—cervical cancer	1.97e-05	8e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—EGFR—cervical cancer	1.97e-05	7.99e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MTOR—cervical cancer	1.96e-05	7.96e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—EGFR—cervical cancer	1.94e-05	7.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MTOR—cervical cancer	1.94e-05	7.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CD4—cervical cancer	1.93e-05	7.85e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—FGFR3—cervical cancer	1.93e-05	7.83e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CTNNB1—cervical cancer	1.93e-05	7.82e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—STAT3—cervical cancer	1.88e-05	7.64e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—STAT3—cervical cancer	1.87e-05	7.59e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—STAT3—cervical cancer	1.87e-05	7.57e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CTNNB1—cervical cancer	1.86e-05	7.55e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—EGFR—cervical cancer	1.84e-05	7.47e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—EGFR—cervical cancer	1.84e-05	7.45e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—EGFR—cervical cancer	1.82e-05	7.4e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CASP3—cervical cancer	1.82e-05	7.39e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—STAT3—cervical cancer	1.82e-05	7.39e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MTOR—cervical cancer	1.82e-05	7.38e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NOTCH1—cervical cancer	1.81e-05	7.35e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CA9—cervical cancer	1.81e-05	7.33e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CASP3—cervical cancer	1.8e-05	7.32e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—EGFR—cervical cancer	1.79e-05	7.27e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MTOR—cervical cancer	1.79e-05	7.25e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—STAT3—cervical cancer	1.78e-05	7.22e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—STAT3—cervical cancer	1.77e-05	7.2e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CTNNB1—cervical cancer	1.76e-05	7.13e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CTNNB1—cervical cancer	1.74e-05	7.06e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CTNNB1—cervical cancer	1.72e-05	6.97e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—EGFR—cervical cancer	1.71e-05	6.95e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—EGFR—cervical cancer	1.7e-05	6.9e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—EGFR—cervical cancer	1.7e-05	6.88e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MTOR—cervical cancer	1.69e-05	6.88e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MTOR—cervical cancer	1.69e-05	6.86e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—STAT3—cervical cancer	1.68e-05	6.82e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CASP3—cervical cancer	1.67e-05	6.79e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—EGFR—cervical cancer	1.65e-05	6.71e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CASP3—cervical cancer	1.64e-05	6.67e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—STAT3—cervical cancer	1.62e-05	6.58e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—EGFR—cervical cancer	1.62e-05	6.56e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—EGFR—cervical cancer	1.61e-05	6.55e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—EGFR—cervical cancer	1.61e-05	6.54e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—MTHFR—cervical cancer	1.61e-05	6.54e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CTNNB1—cervical cancer	1.61e-05	6.54e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CTNNB1—cervical cancer	1.58e-05	6.42e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CASP3—cervical cancer	1.56e-05	6.33e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CASP3—cervical cancer	1.55e-05	6.31e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—STAT3—cervical cancer	1.53e-05	6.21e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—EGFR—cervical cancer	1.53e-05	6.2e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MTOR—cervical cancer	1.52e-05	6.18e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—STAT3—cervical cancer	1.52e-05	6.15e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CTNNB1—cervical cancer	1.5e-05	6.1e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CTNNB1—cervical cancer	1.5e-05	6.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—STAT3—cervical cancer	1.5e-05	6.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—EGFR—cervical cancer	1.47e-05	5.98e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—cervical cancer	1.44e-05	5.83e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STAT3—cervical cancer	1.41e-05	5.7e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CASP3—cervical cancer	1.4e-05	5.68e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EGFR—cervical cancer	1.39e-05	5.64e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—cervical cancer	1.38e-05	5.6e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EGFR—cervical cancer	1.38e-05	5.59e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—MTHFR—cervical cancer	1.36e-05	5.54e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—cervical cancer	1.36e-05	5.52e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—cervical cancer	1.36e-05	5.51e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MTOR—cervical cancer	1.36e-05	5.51e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CTNNB1—cervical cancer	1.35e-05	5.48e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—cervical cancer	1.31e-05	5.31e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—cervical cancer	1.31e-05	5.3e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—cervical cancer	1.28e-05	5.18e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—cervical cancer	1.25e-05	5.09e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—cervical cancer	1.25e-05	5.07e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—cervical cancer	1.22e-05	4.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CTNNB1—cervical cancer	1.2e-05	4.88e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—cervical cancer	1.19e-05	4.83e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—cervical cancer	1.19e-05	4.83e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—cervical cancer	1.19e-05	4.82e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—cervical cancer	1.18e-05	4.78e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—cervical cancer	1.17e-05	4.74e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—cervical cancer	1.16e-05	4.7e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—cervical cancer	1.11e-05	4.51e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—cervical cancer	1.07e-05	4.35e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—cervical cancer	1.07e-05	4.34e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—cervical cancer	1.05e-05	4.27e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—cervical cancer	1.05e-05	4.26e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—cervical cancer	9.99e-06	4.06e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—cervical cancer	9.97e-06	4.05e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—cervical cancer	9.53e-06	3.87e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—cervical cancer	8.98e-06	3.64e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—cervical cancer	8e-06	3.25e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—cervical cancer	7.33e-06	2.97e-05	CbGpPWpGaD
